文献速递肝病

乳糜泻在隐源性肝硬化成人中常见且对无麸质饮食反应良好

Celiac Disease Is Common in Adults With Cryptogenic Cirrhosis and Responds Favorably to Gluten-Free Diet.
PubMed 文献 · Am J Gastroenterol · 2024-11-26

研究筛查232例隐源性肝硬化患者,发现11例(4.7%)经活检确诊乳糜泻;与44例倾向性评分匹配的无乳糜泻患者相比,乳糜泻患者接受无麸质饮食后随访MELDNa和CTP评分显著改善,进一步失代偿更少,死亡率相似。

要点

  • 约4.7%的隐源性肝硬化患者经活检确诊乳糜泻。
  • 乳糜泻患者接受无麸质饮食后MELDNa和CTP评分较无乳糜泻者显著改善。
  • 两组死亡率相似(9.1% vs 18.2%,P=0.67)。

核心结论

  • 约4.7%的隐源性肝硬化患者经活检确诊乳糜泻,其肝脏相关结局随无麸质饮食改善。

研究设计与样本

  • 连续纳入隐源性肝硬化患者,用IgA抗组织转谷氨酰胺酶抗体(anti-tTG)筛查乳糜泻,继以抗肌内膜抗体及十二指肠和肝脏活检,并进行IgA/anti-tTG共定位研究。

主要发现

  • 232例隐源性肝硬化患者中14例anti-tTG抗体高(16.9±10.5倍升高),9例抗肌内膜抗体阳性,11例(4.7%)活检确诊乳糜泻。
  • 7/8肝脏活检和10/11十二指肠活检显示IgA/anti-tTG共定位。
  • 乳糜泻组(n=11)与无乳糜泻匹配组(n=44)基线相似:年龄31.3±7.7 vs 31.8±9.3岁;女性5例(45.5%)vs 15例(34.1%);MELDNa 9(四分位距8-15.5)vs 12(9-15);CTP 7(6-7.5)vs 6(5.75-7)。
  • 随访时乳糜泻组接受无麸质饮食后MELDNa为9(7.5-10.5)vs 无乳糜泻组18.5(12-20),P=0.001;CTP为5(5-5)vs 8(7-9),P<0.001;进一步失代偿更少,死亡率相似(9.1% vs 18.2%,P=0.67)。

临床怎么用

  • 作者认为,隐源性肝硬化患者中约4.7%经活检确诊乳糜泻,无麸质饮食可改善其肝脏相关结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Liver involvement is common in celiac disease (CeD), and up to 4.6% of patients with cryptogenic cirrhosis have CeD. We investigated the prevalence of CeD in patients with cryptogenic cirrhosis and assessed liver-related outcomes in them on GFD when compared with a propensity score-matched cohort of patients with cryptogenic cirrhosis without CeD. METHODS: Consecutive patients with cryptogenic cirrhosis were screened for CeD using IgA anti-tissue transglutaminase antibody (anti-tTG) followed by antiendomysial antibody and duodenal and liver biopsies, on which IgA/anti-tTG colocalization studies were performed. These patients and a cohort of patients with cryptogenic cirrhosis without CeD (1:4 CeD: no CeD matched using propensity score matched for age, sex, Child-Turcotte-Pugh [CTP] and model for end-stage liver disease [MELD]) were initiated on GFD plus standard of care and standard of care, respectively, and followed up for liver-related outcomes for 1 year. RESULTS: Of 232 patients with cryptogenic cirrhosis, 14 had high anti-tTG Ab (16.9 ± 10.5 fold rise), with 9 antiendomysial antibody-positive and 11 (4.7%) biopsy-proven CeD. IgA/anti-tTG Ab colocalization was demonstrated in 7/8 liver and 10/11 duodenal biopsies. Patients with cryptogenic cirrhosis with definite CeD (n = 11) and matched cohort without CeD (n = 44) were similar at baseline (age: 31.3 ± 7.7 vs 31.8 ± 9.3 years; 5 [45.5%] vs 15 [34.1%] females; MELDNa 9 [interquartile-range: 8-15.5] vs 12 [9-15]; CTP 7 [6-7.5] vs 6 [5.75-7]). Patients with CeD on GFD improved significantly on follow-up compared with those without CeD (follow-up MELDNa: 9 [7.5-10.5] vs 18.5 [12-20]; P = 0.001 and follow-up CTP: 5 [5-5] vs 8 [7-9]; P < 0.001) with less frequent further decompensations and similar mortality (9.1% vs 18.2%; P = 0.67). DISCUSSION: Approximately 4.7% of patients with cryptogenic cirrhosis have biopsy-proven CeD, and their liver-related outcomes improve with GFD.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Pachisia AV, Agarwal A, Mehta S, et al. Celiac Disease Is Common in Adults With Cryptogenic Cirrhosis and Responds Favorably to Gluten-Free Diet. Am J Gastroenterol. 2024. PMID: 40315384. doi:10.14309/ajg.0000000000003244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。